$151.72 0.3%
SRPT Stock Price vs. AI Score (Last 150 days)
Data gathered: July 15

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.


Sarepta Therapeutics
Price $151.72
Target Price Sign up
Volume 174,490
Market Cap $14.4B
Year Range $79.15 - $163.85
Dividend Yield 0%
PE Ratio 353.74
Revenue per Employee $1,670,595
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24413M128M286M36M46M0.370
Q4 '23397M135M262M46M46M0.470
Q3 '23332M149M183M-41M-28M-0.460
Q2 '23261M119M142M-24M-9.2M-0.270
Q1 '23254M111M143M-517M-506M-5.860

Insider Transactions View All

Brown Ryan Edward filed to sell 45,267 shares at $160.3.
June 25 '24
Arif Bilal filed to sell 17,363 shares at $163.2.
June 25 '24
Brown Ryan Edward filed to sell 46,242 shares at $159.1.
June 25 '24
Brown Ryan Edward filed to sell 17,129 shares at $164.5.
June 25 '24
Brown Ryan Edward filed to sell 19,678 shares at $163.5.
June 25 '24

Congress Trading View All

Politician Filing Date Type Size
Joshua Gottheimer
Democrat
Aug 21, 23 Buy $1K - $15K
Joshua Gottheimer
Democrat
Jul 11, 23 Sell $1K - $15K
Daniel S. Goldman
Democrat
May 19, 23 Sell $15K - $50K

What is the Market Cap of Sarepta Therapeutics?

The Market Cap of Sarepta Therapeutics is $14.4B.

What is Sarepta Therapeutics' PE Ratio?

As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 353.74.

How Many People Work at Sarepta Therapeutics?

As of our latest update, Sarepta Therapeutics employed approximately 840 people worldwide. However, it's important to note that Sarepta Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Sarepta Therapeutics' revenue per employee?

$1,670,595. To calculate Sarepta Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Sarepta Therapeutics?

Currently, the price of one share of Sarepta Therapeutics stock is $151.72.

How can I analyze the SRPT stock price chart for investment decisions?

The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.

Does SRPT offer dividends to its shareholders?

As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Sarepta Therapeutics?

Some of the similar stocks of Sarepta Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.